Table 1.
Characteristics of patients in study, not in study, and those deceased
| Characteristic | In Study | Not in Study | Deceased | P† |
|---|---|---|---|---|
| n=591 | n=466 | N=358 | ||
| Age at time of surgery (years), mean (SD) | 61.8 (10.3) | 63.0 (11.7) | 70.3 (11.5) | <0.001 |
| BMI at time of surgery (kg/m2), mean (IQR) | 31.4 (25.9,38.7) | 33.3 (27.0,40.0) | 30.8 (25.6,36.5) | <0.001 |
| BMI at time of surgery (kg/m2), N (%) | 0.004 | |||
| Underweight or normal (BMI<24.9) | 124 (21.0) | 75 (16.1) | 75 (21.1) | |
| Overweight (BMI 25.0–29.9) | 138 (23.4) | 91 (19.6) | 90 (25.3) | |
| WHO class I/II (BMI 30.0–39.9) | 201 (34.0) | 181 (38.9) | 137 (38.5) | |
| WHO class III/super obese (BMI 40.0–49.9/50+) | 128 (21.7) | 118 (25.4) | 54 (15.2) | |
| Comorbidities, N (%) | ||||
| History of diabetes at time of the surgery | 106 (17.9) | 111 (23.8) | 75 (20.9) | 0.06 |
| CHF within 30 days prior to the surgery | 2 (0.3) | 2 (0.4) | 8 (2.2) | 0.004 |
| History of renal failure at time of the surgery | 1 (0.2) | 5 (1.1) | 5 (1.4) | 0.08 |
| Surgical details | ||||
| FIGO grade, n (%) | <0.001 | |||
| 1 | 308 (52.1) | 269 (57.7) | 78 (21.8) | |
| 2 | 172 (29.1) | 113 (24.3) | 80 (22.3) | |
| 3 | 111 (18.8) | 84 (18.0) | 200 (55.9) | |
| FIGO stage, n (%) | <0.001 | |||
| I/II | 541 (91.5) | 421 (90.3) | 168 (46.9) | |
| III/IV | 50 (8.5) | 45 (9.7) | 190 (53.1) | |
| LND, N (%) | 0.003 | |||
| No | 191 (32.3) | 181 (38.8) | 99 (27.7) | |
| Yes | 400 (67.7) | 285 (61.2) | 259 (72.3) | |
| Total nodes removed, median (IQR) | 32 (0,53) | 26 (0,48) | 29 (0,46) | 0.06 |
| Pelvic LND, N (%) | 0.004 | |||
| No | 193 (32.7) | 183 (39.3) | 102 (28.5) | |
| Yes | 398 (67.3) | 283 (60.7) | 256 (71.5) | |
| Total pelvic nodes removed, median (IQR) | 25 (0,38) | 21 (0,34) | 23 (0,33) | 0.02 |
| Para-aortic LND, N (%) | 0.09 | |||
| No | 285 (48.2) | 244 (52.4) | 160 (44.7) | |
| Yes | 306 (51.8) | 222 (47.6) | 198 (55.3) | |
| Total para-aortic nodes removed, median (IQR) | 4 (0,15) | 0 (0,14) | 4 (0,13) | 0.43 |
| External beam irradiation therapy, N (%) | 42 (7.1) | 30 (6.4) | 63 (17.6) | <0.001 |
BMI, body mass index; CHF, congestive heart failure; FIGO, International Federation of Gynecology and Obstetrics; IQR, interquartile range; LND; lymphadenectomy; SD, standard deviation; WHO, World Health Organization.
†
F-test P-value from 1-way ANOVA presented for age, Kruskal-Wallis test p-values presented for all other continuous variables and chi-square test P-values presented for categorical variables. P-values less than 0.0033 (=0.05/15) are considered statistically significant after Bonferroni correction for multiple comparisons.